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Abstract
Background: Male breast cancer (MBC) is a rare disease accounting for approximately 1% of all breast carcinomas.
Presently treatment recommendations are derived from the standards for female breast cancer. However, those
approaches might be inadequate because of distinct gender specific differences in tumor biology of breast cancer.
This study was planned in order to contrast potential differences between female and male breast cancer in both
tumor biological behavior and clinical management.
Methods: MBC diagnosed between 1995-2007 (region Chemnitz/Zwickau, Saxony, Germany) was retrospectively
analyzed. Tumor characteristics, treatment and follow-up of the patients were documented. In order to highlight
potential differences each MBC was matched with a female counterpart (FBC) that showed accordance in at least
eight tumor characteristics (year of diagnosis, age, tumor stage, nodal status, grade, estrogen- and progesterone
receptors, HER2 status).
Results: 108 male/female matched-pairs were available for survival analyses. In our study men and women with
breast cancer had similar disease-free (DFS) and overall (OS) survival. The 5-years DFS was 53.4% (95% CI, range
54.1-66.3) in men respectively 62.6% (95% CI, 63.5-75.3) in women (p > 0.05). The 5-years OS was 71.4% (95% CI,
62.1-72.7%) and 70.3% (95% CI, 32.6-49.6) in women (p > 0.05). In males DFS analyses revealed progesterone
receptor expression as the only prognostic relevant factor (p = 0.006). In multivariate analyses for OS both
advanced tumor size (p = 0.01) and a lack of progesterone receptor expression were correlated (p = 0.01) with
poor patients outcome in MBC.
Conclusion: Our comparative study revealed no survival differences between male and female breast cancer
patients and gives evidence that gender is no predictor for survival in breast cancer. This was shown despite of
significant gender specific differences in terms of frequency and intensity of systemic therapy in favor to female
breast cancer.
Background
In contrast to the breast cancer in women, male breast
carcinoma (MBC) is rare, accounting for less than 1% of
all cases of breast carcinoma with an incidence of 1 in
100.000 men [1,2]. In the United States up to 1.500 pri-
mary male breast cancer patients per year were identi-
fied [3]. Data from the SEER Program of the National
Cancer Institute (NCI) showed a slight increase over
time from 1.0 per 100,000 in the late 1970s to about 1.2
per 100,000 in 2000-2004 [4]. Age-standardized rates for
male breast cancer revealed that the incidence peaked in
the year 2000 at 1.24 per 100.000 for men whereas the
peak in women was observed in 1999 at 165 per
100.000 women [1]. Because of its rarity, most informa-
tion about this disease has been obtained from small,
single-institutional or retrospective studies or by extra-
polation from breast cancer trials in women [5]. Its phe-
notypic alterations are not well studied, and therapy is
mainly based on experiences with female breast cancer
[6].
Although both diseases share similarities, there are
notable differences reported [7]. Breast cancer in men
occurs with higher stage, possibly because of delayed
breast cancer detection [2,8]. Male breast cancers also
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receptor–positive [7]. The relatively unfavorable out-
come in male breast cancer has been attributed to more
advanced local tumor stage and high incidence of lymph
node invasion at the time of diagnosis [9-11]. It has
been postulated that close proximity to skin and nipple
facilitates early invasion of lymph vessels leading to ear-
lier regional and distant metastasis.
Gender-comparative survival studies revealed diver-
gent data on patients outcome [11-16]. This might
depend on the lacking adjustment for prognostic rele-
vant parameters in comparative analyses between male
and female cohorts. However, specific informations
about disease outcome in men has emerged great atten-
tion since tailored therapy is of incremental importance
in breast cancer.
Several groups have recently reported comparative
analyses for male versus female breast cancers, but these
studies failed to be adjusted for a variety of prognostic
relevant parameters in breast cancer like age, tumor
size, nodal stage, tumor grade hormone receptors and
HER2 expression [10-16].
To our knowledge this is the first comprehensive gen-
der-specific survival analysis considering all established
tumor and patients characteristics established in female
breast cancer in order to elucidate potential differences
in both disease-free and overall survival.
Methods
Consecutively in the years 1995 to 2007 113 men were
diagnosed with breast cancer in the administrative dis-
trict of Chemnitz in the State of Saxony, Germany. All
data of these patients was obtained from the district’s
two cancer registers located in the cities of Chemnitz
and Zwickau which together oversee a total of about 1.5
million inhabitants. Primary surgery was performed
exclusively in community or district hospitals. Adjuvant
treatment and follow-up care were carried out addition-
ally in outpatient departments. With the approval of the
institutional review boards data regarding patients’ age,
histology, TNM stage, tumor grade, date of diagnosis,
date of metastasizing and date of death were recorded.
In addition, detailed information was gathered on estro-
gen, progesterone and HER2 receptor expression, type
of primary surgery, as well as on chemotherapy, endo-
crine treatment and radiation therapy in the adjuvant
and palliative setting. The study was approved by the
Ethic Committee of the University of Bonn, Germany.
Patient data were collected retrospectively and blinded
(name and date of birth). Therefore and in accordance
with the Ethic Committee patient consent was not
required for the inclusion into the study. For 108 male
breast cancer patients one matching woman could be
chosen from a total of 13.333 female breast cancer
patients. The matching process was based on eight fea-
tures relevant for breast cancer prognosis i.e. year of
diagnosis (within ± 5 year) age, tumor stage, nodal
stage, tumor grade, estrogen and progesterone receptor
expression, as well as HER2 expression. Five men had to
be excluded from the current study because no women
with breast cancer could be matched. If more than one
female patient was eligible the best match was chosen
by random selection. The matching procedure was con-
ducted blinded without any information about patients
outcome.
To ensure the comparability of the male with the
female patients the chi-square test was applied for every
matching criterion. Overall survival (OS) and disease-
free survival estimations were calculated according to
Kaplan and Meier. Disease-free survival (DFS) was
defined as the time period from diagnosis to death of
recurrence or death whichever occurred first. Overall
survival was considered as the time period from first
diagnosis until death. The effect of gender on survival
was estimated by hazard ratio (HR) and its 95% confi-
dence interval (95% CI). P values < 0.05 were considered
statistically significant. All statistical analyses were per-
formed using SPSS version 17.0.
Results
Matching criteria
Based on the above mentioned matching procedure
and under consideration of eight matching criteria 108
male/female pairs were available for survival analyses.
Table 1 displays the distribution of male and female
patients according to the matched tumor characteris-
tics (Table 1). The number of cases in the different
clinicopathological subgroups revealed no significant
gender specific differences. Median age at diagnosis
was 67 years in male and female patients (range, 43–
89 years for men and 36-89 years for women). Less
than 40.0% of the male patients had early tumor stages
(pTis, pT1) whereas 25.0% of the males showed pT4
stages. Four male patients (3.7%) had a ductal cari-
noma in situ, seven (6.5%) were grade 1. Male patients
with lymph node metastasis were found in 43.6%. 10
patients (9.3%) of both gender had primary advanced
disease with distant metastasis. Estrogen and proges-
terone receptor expression was positive in 65.7% and
63.9% respectively. Seven (6.5%) HER2 (3+ immuno-
score and/or FISH amplification) positive male tumors
could be assigned. No age-related distribution of
tumor characteristics could be observed in men. Breast
cancer in younger patients (< 50 years) were not asso-
ciated with tumor parameters representing a more
aggressive phenotype like advanced tumor stage, poor
differentiation and a lack of hormone receptor
expression.
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tionally obtained from patient charts (Table 2): histolo-
gical type, kind of surgery and adjuvant treatment.
Nearly 80% of the tumors in men showed ductal histol-
ogy whereas almost 60% of female cases had a ductal
subtype. It is obvious that male breast cancer was pre-
dominantly treated by mastectomy (88.7%) whereas in
females the rate of mastectomy was 45.4% (p < 0.001).
Axillary dissection was performed in 87.0% of the males
and 85.1% of the female patients (p > 0.05).
More than 60% of the males received adjuvant radio-
therapy whereas in almost 90% of the female patients a
radiation was documented (p < 0.001). Significant differ-
ences regarding adjuvant systemic treatment between
male and female patients were observed: 34% of the
male patients received no adjuvant systemic treatment
whereas only 10.1% of the female patients were without
adjuvant therapy (p < 0.005). Adjuvant endocrine ther-
apy was administered in 48.0% (65.1% in females) of the
male patients consisting of tamoxifen in 43.2% (36.0% in
females), aromatase inhibitors in 4.3% (10.7% in females)
and a switch of tamoxifen and aromatase inhibitors in
0.5% (13.8% in females). 4.6% of the female patients
receive adjuvant GnRH analogues.
A variety of different adjuvant regimens were docu-
mented in male patients. Overall 32.0% of the male
patients (53.9% in females) were treated with adjuvant
chemotherapy. 11.6% of the patients received CMF
(9.3% in females), 11.4% anthracycline containing regi-
mens (34.4% of the females) and 9.0% taxanes (10.2% in
females). In 3.0% of the male patients (1.1% in females)
a trastuzumab containing therapy was administered.
Survival analyses
With a median follow-up time of 56 months (range,1-
143 months) for men and 48 months (range, 1-108
months) for women in our study men and women with
breast cancer showed similar disease-free (DFS) and
overall (OS) survival (Figure 1). 35 (31.0%) male patients
suffered from tumor relapse compared with 28 (25.9%)
cases in women. The 5-years DFS was 53.4% (95% CI,
54.1-66.3) and 62.6% (95% CI, 63.5-75.3) in men and
women, respectively. 36 deaths in men (31.9%) and 32
(29.6%) among women occurred. In both groups 20
(18.5%) of them were attributed to primary cancer. The
5-years OS were 71.41% (95% CI, 62.1-72.7%) and 70.3%
(95% CI, 32.6-49.6) in men and women, respectively.
Table 1 Matching criteria of male and female breast
cancer patients
Men Women Χ
2
Median age (range) 67 (43-89) 67 (36-89)
< 49 9 8.3% 8 7.4% 0.98
50-59 12 11.1% 13 12.0%
60-69 42 38.9% 40 37.0%
70-79 30 27.8% 31 28.7%
> 80 15 13.9% 16 14.8%
Tumor Stage pTis 4 3, 7% 4 3.8% 0.91
pT1 37 35.6% 36 34.6%
pT2 32 30.8% 37 35.6%
pT3 5 4.8% 4 3.8%
pT4 26 25.0% 23 22.1%
Nodal Stage pN0 57 56.4% 56 56.0% 0.85
pN+ 44 43.6% 44 44.0%
Grading G1 7 6.5% 6 6.1% 0.93
G2 62 63.3% 62 62.6%
G3 29 29.6% 31 31.3%
ER-expression ER- 19 17.6% 19 17.6% 1.0
ER+ 71 65.7% 72 66.7%
unknown 18 16.7% 17 15.7%
PR-expression PR- 21 19.4% 22 20.4% 0.86
PR+ 69 63.9% 69 63.9%
unknown 18 16.7% 17 15.7%
HR-expression HR+ 78 72.2% 77 71.3% 0.84
HR- 13 12.1% 14 13.0%
unknown 17 15.7% 17 14.7%
HER2 HER 2 - 70 64.8% 63 58.3% 0.36
HER 2 + 7 6.5% 10 9.3%
unknown 31 28.7% 35 32.4%
Chi-Quadrat test (X
2) was calculated in order to demonstrate accordance
between male and female matching parameters.
Table 2 Not-matched tumor characteristics and treatment
features of female and male breast cancer patients
Men Women c
2
Histology
DCIS 4 3.7% 3 2.8% 0.14
Invasive ductal carcinoma 86 79.6% 64 59.8%
Invasive lobular carcinoma 5 4.6% 16 15.0%
Others* 13 12.0% 25 23.4%
Surgery
Mastectomy 94 88.7% 49 45.4% 0.001
BCS 12 11.3% 51 47.2%
No surgery 0 0% 8 7.4%
Axillary dissection 94 87.0% 92 85.1% 0.76
No axillary dissection 14 13.0% 16 14.8%
Adjuvant radiotherapy
Radio therapy received 62 60.8% 72 87.8% 0.001
No therapy 40 39.2% 10 12, 20%
Adjuvant systemic therapy
Chemotherapy 15 15% 21 23.6% 0.005
Chemo-/Hormone therapy 17 17% 27 30.3%
Hormone therapy 31 31% 31 34.8%
Trastuzumab 3 3% 1 1.1%
No therapy 34 34% 9 10.1%
*Others: mucinous, scirrhous, squamous, mixed.
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cinoma in situ has relapsed. In general, we found no dif-
ference in DFS and OS in the matched pair comparison
between male and female breast cancer patients (Table
3). DFS for tumor stage pT1, however, was significantly
(p = 0.01) reduced in males as compared to females
(Figure 2). It is remarkable that 12/38 (31.6%) male
patients in stage pT1 suffered tumor relapse and died
disease-specifically.
In order to elucidate male gender-specific patients
outcome in men survival analyses were performed addi-
tionally for male patients only (Figure 3). Progesterone
receptor expression was the only prognostic relevant
factor (p = 0.006, univariate analysis only) for DFS. In
addition, univariate analyses revealed tumor stadium,
nodal stage and progesterone receptor expressions as
statistically significantly associated with OS in male
breast cancer. In multivariate analyses for OS both
advanced tumor size (p = 0.01) and a lack of progester-
one receptor expression (p = 0.03) were correlated with
poor patients outcome.
Male breast cancer patient bear a noticeable risk of
secondary cancers. Allover, 21 (19.4%) male breast can-
cer patients had an additional malignant disease, 7
(6.5%) before and 14 (12.9%) after diagnosis of breast
cancer. The most frequent second primary cancers were
prostate, gastric, colorectal carcinoma and skin cancer.
Discussion
In the past decade it has emerged great attention to
obtain evidences about the clinical outcome of male
patients with breast cancer [17-19]. This is due to its
rising incidence and the persistent lack of established
treatment guidelines. Actually, treatment strategies are
derived from female breast cancer [7]. Without evi-
dence-based data to support female-to-male extrapola-
tion, epidemiologic comparisons become an alternative
source of information.
A couple of features in male breast cancer are of par-
ticular interest. Male breast cancer was more like late-
onset than female breast cancer with more than 90% of
male patients aged 50 years and older. It is well known
that breast cancer in men is diagnosed 5 to 10 years
later than in women [20] which also might account for
the less aggressive adjuvant treatment modalities given
to male patients in this study.
Furthermore, more than 90% of male breast carcino-
mas were hormone receptor positive whereas less than
10% overexpressed HER2. This is in line with previous
findings [21,22] and supports the hypothesis that the
luminal like molecular subtype is predominant in men
[20,23,24]. As opposed to female breast cancer the pro-
gesterone receptor expression in men was an indepen-
dent prognostic factor in this study.
Male patients had a significant proportion of advanced
tumor stages (pT2-4 > 60%) and more than 40% showed
nodal involvement [25]. This is at least in part caused
by a delay of diagnosis in men of more than six months
in average [26-28]. There is little public awareness of
breast carcinoma in men and public education regarding
the existence of male breast carcinoma. No recommen-
dations for self-examination or examination of the male
Figure 1 Gender-specific DFS (a) and OS (b) of the matched-pair study group.
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Page 4 of 8breast by physicians exist. No guidelines recommend
screening mammography at any age for men because of
the rarity of the disease.
In male breast cancer adjuvant treatment was admi-
nistered less frequently. Almost one third of men
received no adjuvant treatment as compared to 10% in
the matched-pair female group. Only 32% of male
patients had adjuvant chemotherapy (54% in women)
and less than 50% adjuvant endocrine treatment (65%
in women). Nevertheless, our comparative study
revealed no survival differences between male and
female breast cancer patients and gives evidence that
gender is no predictor for neither disease-free nor
overall survival. These findings are remarkable consid-
ering the different systemic treatment given to male
patients as compared to the matched female patients.
Due to exact matching procedures with respect to all
established clinical and pathological prognostic factors
(Table 1), a gender specific bias of prognostic features
seems unlikely.
In addition, considering clinically relevant subgroups
no significant overall survival differences could be
observed between men and women. In our study men
with pT1 tumors had significantly worse DFS compared
Table 3 Gender-specific DFS and OS according to the matching criteria of the study group
DFS OS
Men [median
months]
Women [median
months]
p-
Value*
Men [median
months]
Women [median
months]
p-
Value*
Study group
Age ≤ 49 94 91 n.s. 115 127 n.s.
50-59 61 65 n.s. 105 73 n.s.
60-69 79 85 n.s. 108 85 n.s.
70-79 49 51 n.s. 61 65 n.s.
≥ 80 68 39 n.s. 80 51 n.s.
Tumor stage pT1 69 90 0.01 98 127 n.s.
pT2 79 85 n.s. 95 99 n.s.
pT3 50 67 n.s. 76 82 n.s.
pT4 47 32 n.s. 41 39 n.s.
Lymphnodes pN0 79 85 n.s. 103 106 n.s.
pN+ 38 42 n.s. 80 63 n.s.
Metastases cM0 - - 99 96 n.s.
cM1 - - 10 8 n.s.
Grading G1** - - - -
G2 94 88 n.s. 103 90 n.s.
G3 72 76 n.s. 80 78 n.s.
Estrogen receptor ER- 82 70 n.s. 41 76 n.s.
ER+ 81 119 n.s. 108 127 n.s.
Unknown 97 67 n.s. 86 57
Progesterone receptor
PgR-
38 91 n.s. 38 58 n.s.
PgR+ 77 154 n.s. 108 127 n.s.
Unknown 97 75 n.s. 86 76 n.s.
HER2 receptor HER2- 77 91 n.s. 108 127 n.s.
HER2+ 36 57 n.s. 41 68 n.s.
* p-value < 0.05 was calculated to be statistically significant
** none of the patients had tumor relapse or died.
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Figure 2 Gender-specific DFS (a) and OS (b) for tumor stage pT1. Males with pT1 tumor showed a significantly reduced DFS (p = 0.02).
a) b)
c) d)
e) f)
Figure 3 DFS and OS of male patients according to prognostic relevant tumor characteristics: Tumor (T) stage (a, b), nodal (N) status
(c, d), and progesterone receptor (PR) status (e, f). p < 0.05 is considered as statistically significant.
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Page 6 of 8to females. Those male patients with pT1 tumors who
have relapsed so far showed no poor prognostic features
e.g. all of them were hormone receptor positive.
Furthermore, all of them received adjuvant tamoxifen.
Therefore, no specific predictors for metastasis in this
low risk group could be identified. Potential explana-
tions for a comparatively worse outcome of males with
early breast cancer are obviously. There is no evidence
that tamoxifen is highly effective in primary male breast
cancer patient. Data supporting response to treatment
are mainly retrospective or from small trials [29]. There
are major concerns regarding patients compliance and
tamoxifen metabolic activity which might have negative
impact on the efficacy. Clinical response to tamoxifen
depends on the biotransformation via the cytochrome
P450 isoenzyme CYP2D6 isoform, to the active metabo-
lite endoxifen. CYP2D6 activity can be reduced in men
both by genetic variation or concurrent use of drug
inhibitors, which can significantly reduce endoxifen
plasma concentrations [30]. However, tamoxifen remains
the standard therapy in endocrine responsive male
breast cancer and clincial and translational studies on
this field are needed.
Our cohort study has several limitations and selection
bias regarding the match pair analysis could not be
excluded. Beside its retrospective character the number
of male patients is small compared to female studies.
Therefore analyses especially of patients subgroups has
limited clinical significancy.
Several other groups compared male and female breast
cancer features and prognosis [10,11,15,31-33] with
divergent results. Marchal and colleagues found similar
DFS but worse OS for male as compared to female breast
cancer patients in a retrospective study [11]. The authors
explained the OS difference with a higher amount of
comorbidities in men. However, the study was based on
matched-pair analyses of only 58 male breast carcinomas
and three matching criteria (age, year of diagnosis, stage).
Tumor differentiation, hormone receptor status and
HER2 positivity were not considered. This might reflect
an incomplete matching procedure and could better
explain the divergent findings to our results.
Conclusion
Our retrospective study showed no disease and overall
survival differences between male and female breast can-
cer patients matched for year of diagnosis, age, tumor
size, nodal stage, tumor grade, estrogen receptor, pro-
gesterone receptor and HER2 expression. This is of
great importance since male patients receive obviously
less aggressive adjuvant treatment.comparted their
female matched pairs. A significantly reduced DFS in
male with pT1 tumors was found. In multivariate ana-
lyses only early stage and progesterone receptor positvity
were statistically significant related to improved overall
survival in male breast cancer.
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